Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography

Biomedical Chromatography

Volumn 21, Issue 7, 2007, Pages 747-754

  Oostendorp, Roos L ^a   Beijnen, Jos H ^b   Schellens, Jan H M ^a,b   van Tellingen, Olaf ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

CGP74588; HPLC; Human plasma; Imatinib mesylate; Murine specimens

Indexed keywords

AMINO ACIDS; BIOMOLECULES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PLASMA (HUMAN);

B-Y IONS; CGP74588; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC; HUMAN PLASMAS; IMATINIB; IMATINIB MESYLATE; ION-PAIRING; MURINE SPECIMEN; PERFORMANCE; REVERSED-PHASE HIGH PERFORMANCE;

METABOLITES;

4 HYDROXYBENZOPHENONE; ACETONITRILE; AMMONIUM ACETATE; BENZOPHENONE DERIVATIVE; CGP 74588; DRUG METABOLITE; IMATINIB; N NORIMATINIB; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

MURINAE; MUS;

EID: 34447550647     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.816     Document Type: Article

References (33)

1. Bakhtiar R, Khemani L, Hayes M, Bedman T and Tse F. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2002a; 28(6): 1183-1194.
2. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M and Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2002b; 768(2): 325340.
3. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB and Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-571481. Clinical Cancer Research 1998; 4(7): 1661-1672.
4. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH and Schellens JH. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Research 2005; 65: 2577-2582.
5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. Journal of Pharmacology Experimental Therapeutics 2000; 295(11: 139-145.
6. Capdeville R, Buchdunger E, Zimmermann J and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery 2002; 1(7): 493-502.
7. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90(121: 4947-4952.
8. Dai H, Marbach P, Lemaire M, Hayes M and Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. Journal of Pharmacology Experimental Therapeutics 2003; 304: 1085-1092.
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD and Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 26112: 347: 472-480.
10. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Annals of Oncology 26115; 16: 1702-1708.
11. Druker BJ and Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Journal of Clinical Investigation 26110; 105(11: 3-7.
12. Druker BJ, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001; 344: 1031-1037.
13. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben Am M, Peng B and Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metabolism and Disposition 2005; 33(101: 1503-1512.
14. Guetens G, De Boeck G, Highley M, Dumez H, van Oosterom AT and de Bruijn EA. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 2003; 1020(1): 27-34.
15. Guetens G, Prenen H, De Boeck G, Highley M, de Wever I, van Oosterom AT and de Bruijn EA. Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. Journal of Separation Science 2006; 29(3): 453-459.
16. Hamada A, Miyano H, Watanabe H and Saito H. Interaction of imatinib mesilate with human P-glycoprotein. Journal of Pharmacology Experimental Therapeutics 2003; 307(2): 824-828.
17. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 20611; 96(3): 925-932.
18. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R and Le Chevalier T. Phase II study of imatinib in patients with small cell lung cancer. Clinical Cancer Research 26113; 9(16 Pt 1): 5880-5887.
19. Marull M and Rochat B. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. Journal of Mass Spectrometry 2006; 41(31: 390-404.
20. McCormick F. New-age drug meets resistance. Nature 2001; 412(68441: 281-282.
21. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG and Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(91: 3130-3135.
22. Parise RA, Ramanathan RK, Hayes MJ and Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2003; 791(1-21: 39-44.
23. Peng B, Lloyd P and Schran H. Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics 26115; 44: 879-894.
24. Ramalingam S, Lagattuta TF, Egorin MJ, Hayes MJ and Ramanathan RK. Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy 2004; 24(9): 1232-1235.
25. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P and DiPaola RS. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005; 62(2): 115-122.
26. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Sr., Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ and Friedman HS. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology 2005; 23: 9359-9368.
27. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clinical Pharmacokinetics 26115; 44(4):349-366.
28. Schleyer E, Pursche S, Kohne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner M, Bornhauser M, Ottmann OG and Ehninger G. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life, Sciences 2004; 799(1): 23-36.
29. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17(12): 1551-1557.
30. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002;2(2): 99-102.
31. Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P, Mahon FX and Molimard M. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring 26115; 27(5): 634-640.
32. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L and Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2004; 804(2): 431-434.
33. Widmer N, Beguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J and Decosterd LA. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2004; 803(2): 285-292.